Michael Soldan, PhD
Djordje Filipovic, PhD
Eduardo Schiffrin, MD
Dr Michael Soldan is an experienced Pharmaceutical Executive with a solid background in General Management as well as a proven track record of achievement in the development and commercialization of biologics (biosimilars, innovative monoclonal antibodies, recombinant proteins, vaccines and blood products) and small molecules. His experience extends to executive positions in companies of different size.
As CEO of AB2 Bio Michael will lead the company in the development and commercialization of Tadekinig alfa and will be responsible for successfully progressing AB2 Bio as a company.
Previously, as the CEO of the Biosimilars Business at Fresenius Kabi, Michael managed the development, manufacturing and strategic commercialization of all their Biosimilars worldwide. Prior to this, he was SVP at Merck KgaA in Aubonne where he was responsible for establishing and expanding the Biosimilar Business within Merck KgaA and then transitioning it to Fresenius Kabi in 2017.
Earlier in his career he led Medical and Regulatory functions at Boehringer Ingelheim, Biotest AG, Grünenthal, Novartis Vaccines and Aventis.
Michael holds a PhD in Pharmacology and has degrees in Pharmacy and Theoretical Medicine (Human Biology) from the Philipps-University in Marburg, Germany.
Mr. Cunha has several years of experience in Finance, Controlling, Tax and related matters. His career began with BDO where he held various positions in Switzerland and Australia. In 2009, he joined AC Immune SA in Lausanne, Switzerland as Head of Accounting and Finance Controlling and then Head of Financial Operations. Prior to joining AB2 Bio in September 2014, Mr. Cunha was Manager at KPMG Switzerland in the Business and Outsourcing Services department. Mr. Cunha is a Swiss Certified Expert for Finance and Controlling.
Dr Djordje Filipovic is a multifaceted Pharmaceutical Executive with more than 20 years of experience in Research, Development, Marketing, Strategic Functions and General Management at local, regional and global levels. During his career he was overseeing the development and commercialization of some key Novartis small molecule and monoclonal antibody assets in Pharmaceuticals and Oncology and also served as Chairman of the Novartis Oncology Portfolio Management Board.
As CCO of AB2 Bio Djordje will lead the commercialization of Tadekinig alfa and will contribute to successfully progressing AB2 Bio as a company.
Previously, Djordje was the Global Head of Learning for Novartis Pharmaceuticals building an integrated function across functional and personal learning for the Division. Prior to that, he served as Group General Manager of Novartis in Iran where he was directly accountable for all Novartis Divisions & Units and responsible for setting the foundation for transformational growth.
Earlier in his career at Novartis Djordje was General Manager for the Immunology, Dermatology & Hepatology on the AMAC (Asia Middle East Africa) Regional Executive Committee and the Oncology Business in Switzerland. He also led the Global Pharma Brand Maximization and Oncology Project & Portfolio Management functions.
Prior to joining the Research Division of Sandoz, a predecessor Company of Novartis, in 1992, as a laboratory head, Djordje worked in the field of Protein Engineering at the University of Illinois and Battelle Labs with the U.S. Department of Energy.
Djordje is a graduate of the Swiss Federal Institute of Technology (ETH) in Zürich, holding a Ph.D. in Biochemistry & Biophysics. He currently lectures at the European Center of Pharmaceutical Medicine (ECPM) and Medical School of the Basel University on Portfolio Management, Trends in Drug Development and Leadership. Djordje is also a member of the Advisory Board of the ECPM and an elected member of the Scientific Counsel of the Swiss Academy of Technical Sciences (SATW).
Dr. Schiffrin obtained his medical degree from La Plata University, Argentina, and was a research fellow at Harvard University where he studied mucosal immunology. He is a specialist in human pathology and inflammatory and immunological diseases. Before joining AB2 Bio he was a Medical Director for Nestlé Global Research and has been involved in the clinical development of multiple medical products treating inflammatory diseases and allergies.